Alnylam Pharmaceuticals (ALNY) Change in Receivables (2009 - 2026)

Alnylam Pharmaceuticals' Change in Receivables history runs 18 years deep, the most recent figure standing at $110.4 million for Q1 2026.

• Quarterly Change in Receivables rose 1385.35% year-over-year to $110.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $463.0 million (up 390.44% YoY) and the FY2025 annual result came in at $360.0 million, up 315.9% from the prior year.
• Change in Receivables was $110.4 million for Q1 2026 at Alnylam Pharmaceuticals, up from -$184.2 million in the prior quarter.
• Across five years, Change in Receivables topped out at $399.9 million in Q3 2025 and bottomed at -$184.2 million in Q4 2025.
• A 5-year average of $40.6 million and a median of $7.4 million in 2025 frame the typical range for Change in Receivables.
• Annual changes were most pronounced in 2022 — Change in Receivables tumbled 470.68% — and 2025, when it jumped 1913.17%.
• Alnylam Pharmaceuticals' Change in Receivables stood at $53.3 million in 2022, then plunged by 107.26% to -$3.9 million in 2023, then soared by 1638.07% to $59.5 million in 2024, then slumped by 409.62% to -$184.2 million in 2025, then soared by 159.93% to $110.4 million in 2026.
• Business Quant data shows ALNY's Change in Receivables at $110.4 million in Q1 2026, -$184.2 million in Q4 2025, and $399.9 million in Q3 2025.